People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Goldfinch Bio, Inc. | — | Pharmaceuticals | Series C | $69.7M | $2.4B | 2020 |
JEAN-CHRISTOPHE HARMANGE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JEAN-CHRISTOPHE HARMANGE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ABBIE CELNIKER | 1 | 6 |
| NEIL EXTER | 1 | 5 |
| Anthony Johnson | 1 | 3 |
| Kyle Kuvalanka | 1 | 3 |
| Wen Chen | 1 | 3 |
| Louis Brenner | 1 | 2 |
| JOY GHOSH | 1 | 1 |
| FRANK CZERWIEC | 1 | 1 |
| LORI RUDOLPH-OWEN | 1 | 1 |
| CURTIS DEMICK | 1 | 1 |
| FRANK MADDUX | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.